Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Braz. j. med. biol. res ; 45(4): 328-336, Apr. 2012. ilus
Article in English | LILACS | ID: lil-622754

ABSTRACT

The hypothalamus is a forebrain structure critically involved in the organization of defensive responses to aversive stimuli. Gamma-aminobutyric acid (GABA)ergic dysfunction in dorsomedial and posterior hypothalamic nuclei is implicated in the origin of panic-like defensive behavior, as well as in pain modulation. The present study was conducted to test the difference between these two hypothalamic nuclei regarding defensive and antinociceptive mechanisms. Thus, the GABA A antagonist bicuculline (40 ng/0.2 µL) or saline (0.9% NaCl) was microinjected into the dorsomedial or posterior hypothalamus in independent groups. Innate fear-induced responses characterized by defensive attention, defensive immobility and elaborate escape behavior were evoked by hypothalamic blockade of GABA A receptors. Fear-induced defensive behavior organized by the posterior hypothalamus was more intense than that organized by dorsomedial hypothalamic nuclei. Escape behavior elicited by GABA A receptor blockade in both the dorsomedial and posterior hypothalamus was followed by an increase in nociceptive threshold. Interestingly, there was no difference in the intensity or in the duration of fear-induced antinociception shown by each hypothalamic division presently investigated. The present study showed that GABAergic dysfunction in nuclei of both the dorsomedial and posterior hypothalamus elicit panic attack-like defensive responses followed by fear-induced antinociception, although the innate fear-induced behavior originates differently in the posterior hypothalamus in comparison to the activity of medial hypothalamic subdivisions.


Subject(s)
Animals , Male , Rats , Dorsomedial Hypothalamic Nucleus/physiology , Escape Reaction/physiology , Hypothalamus, Posterior/physiology , Panic Disorder/metabolism , Bicuculline/pharmacology , Dorsomedial Hypothalamic Nucleus/drug effects , GABA-A Receptor Antagonists/pharmacology , Hypothalamus, Posterior/drug effects , Maze Learning , Pain Threshold/drug effects , Panic Disorder/etiology
2.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 29(supl.1): s3-s6, maio 2007.
Article in Portuguese | LILACS | ID: lil-452225

ABSTRACT

OBJETIVO: Este artigo discute a ativação diferencial do eixo hipotálamo-pituitária-adrenal no transtorno de ansiedade generalizada e no transtorno de pânico. MÉTODO: Resultados de recentes revisões da literatura são resumidos e discutidos. RESULTADOS: Os resultados de estudos experimentais que dosaram o hormônio adrenocorticotrópico, o cortisol e a prolactina mostram que ataques de pânico naturais, bem como os provocados por agentes panicogênicos seletivos - como lactato de sódio e dióxido de carbono -, não ativam o eixo hipotálamo-pituitária-adrenal. Agonistas do receptor de colecistocinina do tipo B, como o peptídeo colecistocinina-4 e a pentagastrina, elevam os hormônios de estresse, independentemente da ocorrência de um ataque de pânico, parecendo ativar diretamente o eixo hipotálamo-pituitária-adrenal. O antagonista benzodiazepínico flumazenil não eleva o nível dos hormônios de estresse; porém, este agente farmacológico não induz ataques de pânico de modo consistente. Agentes farmacológicos que aumentam a ansiedade em pacientes de pânico (cafeína, ioimbina, agonistas serotonérgicos), assim como em pessoas saudáveis, elevam o nível dos hormônios de estresse. CONCLUSÕES: Além das diferenças na sintomatologia e na resposta farmacológica, o transtorno de ansiedade generalizada e o transtorno de pânico afetam os hormônios de estresse de modo distinto. Enquanto a ansiedade antecipatória e o transtorno de ansiedade generalizada ativam tanto o eixo hipotálamo-pituitária-adrenal como o simpático-adrenal, o ataque de pânico causa acentuada ativação simpática; porém, afeta pouco o eixo hipotálamo-pituitária-adrenal.


OBJECTIVE: This article focuses on the differential activation of the hypothalamic-pituitary-adrenal axis in generalized anxiety disorder and panic disorder. METHOD: The results of recently reported reviews of the literature are summarized and discussed. RESULTS: The results of experimental studies that assayed adrenocorticotropic hormone, cortisol and prolactin show that real-life panic attacks, as well as those induced by selective panicogenic agents such as lactate and carbon dioxide, do not activate the hypothalamic-pituitary-adrenal axis. Agonists of the cholecystokinin receptor B such as the cholecystokinin-4 peptide and pentagastrin increase stress hormones regardless of the occurrence of a panic attack and, thus, seem to activate the hypothalamic-pituitary-adrenal axis directly. The benzodiazepine antagonist flumazenil does not increase stress hormones, but this agent does not reliably induce panic attacks. Pharmacological agents that increase anxiety in both normal people and panic patients (caffeine, yohimbine, serotonergic agonists) raise stress hormone levels. CONCLUSIONS: In addition to the differences in symptomatology and pharmacological response, generalized anxiety disorder and panic disorder affect stress hormones in distinct ways. While anticipatory anxiety and generalized anxiety disorder activate both the hypothalamic-pituitary-adrenal and the sympathoadrenal axes, panic attack causes major sympathetic activation, but has little effect on the hypothalamic-pituitary-adrenal axis.


Subject(s)
Animals , Humans , Hypothalamo-Hypophyseal System/physiopathology , Panic Disorder/physiopathology , Pituitary-Adrenal System/physiopathology , Stress, Psychological/physiopathology , Adrenocorticotropic Hormone/metabolism , Carbon Dioxide/metabolism , Disease Models, Animal , Hypothalamo-Hypophyseal System/metabolism , Lactic Acid/metabolism , Panic Disorder/metabolism , Panic Disorder/psychology , Pituitary-Adrenal System/metabolism , Prolactin/metabolism , Stress, Psychological/metabolism
3.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 25(supl.2): 42-45, dez. 2003. ilus
Article in Portuguese | LILACS | ID: lil-355612

ABSTRACT

Este artigo é uma revisäo de evidências experimentais e construtos teóricos que implicam a modulaçäo do comportamento de defesa pela serotonina (5-HT), atuando na matéria cinzenta periaquedutal do mesencéfalo (MCP) no transtorno do pânico. Resultados obtidos com testes de conflito em animais de laboratório indicam que a 5-HT aumenta a ansiedade, enquanto que a estimulaçäo aversiva da MCP aponta para um papel ansiolítico. Para resolver esta contradiçäo, sugeriu-se que os estados emocionais determinados pelos dois paradigmas säo diferentes. Testes de conflito gerariam ansiedade antecipatória, enquanto que a estimulaçäo da MCP produziria medo de perigo iminente. Clinicamente, o primeiro estado estaria relacionado com o transtorno de ansiedade generalizada e o segundo, com o transtorno do pânico. Assim sendo, supöe-se que a 5-HT facilita a ansiedade, porém inibe o pânico. Esta hipótese tem sido testada por meio de um modelo animal de ansiedade e pânico, denominado labirinto em T-elevado, e de dois procedimentos experimentais que geram ansiedade, aplicados tanto em voluntários sadios como em pacientes de pânico. Em geral, os resultados obtidos até agora mostram que drogas que aumentam a açäo da 5-HT elevam diferentes índices de ansiedade, enquanto reduzem índices de pânico. Portanto, as prediçöes baseadas na hipótese em questäo têm se cumprido. As principais implicaçöes clínicas säo as de que um déficit de 5-HT na MCP possa participar da fisiopatogenia do transtorno de pânico e que a intensificaçäo da 5-HT na mesma regiäo medeie a açäo antipânico dos medicamentos antidepressivos


Subject(s)
Animals , Serotonin Agents/pharmacology , Serotonin/pharmacology , Periaqueductal Gray , Panic Disorder/drug therapy , Models, Animal , Anxiety/metabolism , Anxiety/drug therapy , Behavior, Animal , Periaqueductal Gray/metabolism , Panic Disorder/metabolism
4.
Arq. neuropsiquiatr ; 58(2B): 408-11, jun. 2000. tab
Article in English | LILACS | ID: lil-264437

ABSTRACT

Serum plasma total cholesterol levels were measured in 85 male or female outpatients with panic disorder (PD; N=41), generalized anxiety disorder (GAD; N=23) and major depression (MD; N=21) according to DSM-IV criteria. All the patients had a mean cholesterol level within the normal range; males (N=22) and females (N=63) had approximately the same serum cholesterol levels (p > .05). No significant differences in cholesterol levels emerged between PD, GAD and MD patient groups. Both female PD and female GAD subjects had a mean cholesterol level similar to their male counterparts (p>.05). It is concluded that both Hayward and colleagues and Bajwa et al. findings could not be replicated by our study.


Subject(s)
Humans , Male , Female , Adult , Anxiety Disorders/metabolism , Cholesterol/blood , Depression/metabolism , Panic Disorder/metabolism , Analysis of Variance , Anxiety Disorders/blood , Cholesterol/metabolism , Depression/blood , Panic Disorder/blood
SELECTION OF CITATIONS
SEARCH DETAIL